HemaSphere
 2023
DOI: 10.1097/01.hs9.0000975796.49668.c2
|View full text |Cite
|
Sign up to set email alerts
|

Pb2266: Trial in Progress: Phase 3 Trial of Odronextamab Plus Lenalidomide Versus Rituximab Plus Lenalidomide in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma (Olympia-5)

Umberto Vitolo
1
,
E. Phillips
2
,
Aránzazu Alonso Alonso
3
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The ELM-2 study 7 aims to evaluate the efficacy and safety of odronextamab monotherapy in relapsed or refractory marginal zone lymphoma (R/R MZL). Additionally, the OLYMPIA-5 trial 8 also aims to evaluate the efficacy and safety of odronextamab plus lenalidomide compared to the R 2 regimen in R/R MZL.…”
Section: Cd20 × Cd3 Bites In Marginal Zone Lymphomamentioning
confidence: 99%

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting

Jin,
Liu,
Zhang
et al. 2023
Therapeutic Advances in Chronic Disease
1
0
0
0
View full textAdd to dashboardCite
show abstract
“…The ELM-2 study 7 aims to evaluate the efficacy and safety of odronextamab monotherapy in relapsed or refractory marginal zone lymphoma (R/R MZL). Additionally, the OLYMPIA-5 trial 8 also aims to evaluate the efficacy and safety of odronextamab plus lenalidomide compared to the R 2 regimen in R/R MZL.…”
Section: Cd20 × Cd3 Bites In Marginal Zone Lymphomamentioning
confidence: 99%

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting

Jin,
Liu,
Zhang
et al. 2023
Therapeutic Advances in Chronic Disease
1
0
0
0
View full textAdd to dashboardCite
show abstract

The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds

Ellerman
2024
BioDrugs
0
0
0
0
View full textAdd to dashboardCite
scite logo

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product
Browser ExtensionAssistant by sciteCitation Statement SearchReference CheckVisualizationsDashboardsExplore JournalsExplore OrganizationsExplore FundersEmbedding BadgeEmbedding Citation SearchPricing
Resources
BlogHelp & FAQAccessibility StatementAPI TermsFor Universities & GovernmentsFor ResearchersFor PublishersFor Corporate, Pharma & EnterpriseAuthor MarketingBecome an AffiliateGet an organization trial or quotescite Data & Services
About
News & PressCareersRead our PaperCoverage

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BlogTerms and ConditionsAPI TermsPrivacy PolicyContactCookie PreferencesDo Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.